A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.
about
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis CRibavirin plus interferon versus interferon for chronic hepatitis CRibavirin plus interferon versus interferon for chronic hepatitis CRetreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]Hepatitis C virus: Promising discoveries and new treatmentsDe novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virusStructure-Based Mutational Analysis of the Hepatitis C Virus NS3 HelicaseA peptide derived from RNA recognition motif 2 of human la protein binds to hepatitis C virus internal ribosome entry site, prevents ribosomal assembly, and inhibits internal initiation of translation.Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.Clinical guidelines on the management of hepatitis CA rational approach to the management of hepatitis C infectionHepatology.WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C.Efficacy and tolerability of combination therapy with interferon-alfa plus ribavirin in patients with chronic hepatitis C virus infection: a single-center study in relapsers and nonresponders to previous treatment with high-dose interferon-alfa monoMutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy andTreatment of chronic hepatitis C: impact of combination therapy.Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).Management of viral hepatitis C.Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon.Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters.Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.Potassium Dehydroandrographolide Succinate Injection for the treatment of child epidemic parotitis: A systematic review and meta-analysis.Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options.Therapy of hepatitis C: from empiricism to eradication.Response of TT virus to IFN plus ribavirin treatment in patients with chronic hepatitis CCombination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapyNew treatment strategies against hepatitis C viral infection.Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms.Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.Boceprevir and personalized medicine in hepatitis C virus infectionPharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.Support for patients with hepatitis C: an exploratory qualitative study of medical specialists' perceptions.Hepatitis in patients with end-stage renal disease.Viral hepatitis in older adults.Adding interventions to interferon in chronic HCV infections
P2860
Q24201588-0A0F8DFF-9499-4355-A96E-30C955E86AB7Q24240879-CFD1F8DA-2C74-4132-8C08-E91001C9526AQ24244070-5BF6D60F-EB97-4336-A79F-08B95A5615A2Q24805127-5CDF97CA-94A5-4B91-8E6B-CD1C402703EAQ27468916-629DB750-9287-47C3-B752-B25AF930A312Q27469625-A67A05C1-52ED-448A-A231-D605F21B5617Q27469958-AD5A3F6A-43C1-4D5C-A23C-ABF98B9D67BCQ27470332-6E5EA59D-8F4C-4D81-99FA-610EABCDC953Q27473018-AD8A73CA-701A-4A80-A907-C0CBCE58E44BQ27477946-F4BD18AA-5BEC-4C95-AF91-C83BA5E390B6Q27485902-BB38A189-46A4-4EB9-8EF9-9981917AB800Q27486937-0D7AB967-A48F-4194-8338-E70D953DE791Q33291074-1116862B-9DF8-4FAD-AB01-F75F7DC1FF4BQ33739046-1C479FAF-F62E-4688-A8AA-AE12163B93C3Q33866399-AF13AFB0-7239-4908-A94B-8F8180B13533Q34027571-3075919F-7222-4142-973D-2FB2FBA5E795Q34605831-67F929F9-3ADB-4692-8288-ECEBC6D1D45DQ34631375-04D3922D-1AB5-41C9-84FB-D860AF07FE8AQ34799386-0E3FD1E1-57B2-4C5E-8614-632A14DA7491Q34799396-01F33BBA-DE14-461C-937B-1BCF6B1C6A4DQ35027450-F9F5433B-8B9D-4DCC-B204-8B791DA3D581Q35041900-CFDBC378-510F-4C5A-A7B3-D269137FD930Q35505366-DC160DED-D0A0-47BE-8174-C14EB6480C3BQ35802787-1FBACABF-7CEF-49D8-B434-41E1B9C04E2AQ35824821-026467BA-52DE-4132-9292-729D45E7CF82Q36382235-45338063-F19C-45E8-952F-E9A6D9A0CE15Q36474563-C377FBEC-6A8D-4E32-BC1D-ABAE347E61AAQ36491967-54E4E828-1FCB-4A02-8221-D3D01CEF6B72Q36655935-1C589579-5C55-4127-B629-95BE03AC771BQ37050953-16046C45-78FE-4C8E-B6FD-708D507054B2Q37340946-75400756-4D09-49B1-BA99-48E69351C1D0Q37627878-AF445ADC-18FD-45D3-A5A2-4168EDECE54FQ37972769-69AC7CBE-728F-431C-8308-D571AE3BA58AQ38066185-BFDF81C0-F236-4F17-8D05-C1473E3E0848Q39471947-BCFB18DD-85C7-4962-91C0-FFDB26BF4F64Q40605824-D012A5CB-7058-4968-96BD-098A48F332E6Q40813429-B593CC60-E278-4AE8-8559-451F912B93D7Q40874165-9A345EF1-088B-4EDE-A422-62F6CA29CF4DQ41495778-BCFD1A8F-117C-4411-BB92-7C880A027871Q42278524-6306FE89-08F8-4121-80DD-5A035188DCD9
P2860
A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
A pilot study of combination t ...... resistant chronic hepatitis C.
@en
A pilot study of combination t ...... resistant chronic hepatitis C.
@nl
type
label
A pilot study of combination t ...... resistant chronic hepatitis C.
@en
A pilot study of combination t ...... resistant chronic hepatitis C.
@nl
prefLabel
A pilot study of combination t ...... resistant chronic hepatitis C.
@en
A pilot study of combination t ...... resistant chronic hepatitis C.
@nl
P2093
P1433
P1476
A pilot study of combination t ...... -resistant chronic hepatitis C
@en
P2093
M Miglioli
R Deaville
S Brillanti
P304
P356
10.1016/0016-5085(94)90131-7
P407
P577
1994-09-01T00:00:00Z